Received by email:

File: InMed - CMO.docx


/
 

CSE:IN
OTCQB: IMLFF

Suite 350- 409 Granville ST
Vancouver, BC, Canada V6C-1T2
Tel: 604.669.7207
Email: info@inmedpharma.com
www.inmedpharma.com
 
 
InMed Pharmaceuticals Appoints Dr. Abo Mohammed as
 Chief Medical Officer


Vancouver, BC - March 4, 2015 -InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage biophar
--->maceutical company specializing in the development of cannabinoid based therapies, today announced that it has appoint
--->ed former Associate Medical Director of GW Pharmaceuticals, Abo Mohammed, MD, DPM, MFPM, as Chief Medical Officer, eff
--->ective immediately.  Dr. Mohammed is a proven leader in the development of cannabinoid therapies, having played a stra
--->tegic role in the clinical development, R&D, and commercialization of these specialty drugs.

As Chief Medical Officer, Dr. Mohammed will join InMed's executive management team and will be directly involved in de
--->veloping the clinical trial strategy for InMed's lead candidates and product development strategy for the Company's pi
--->peline of cannabinoid based therapies, including its two clinical stage programs,CTI-085 and CTI-091, and the recently
---> initiated program for Epidermolysis bullosa simplex (EBS), INM-750.
"Our recent progress and anticipated advancement of our lead drug candidates have made the creation of the Chief Medic
--->al Officer position a corporate priority," commented Craig Schneider, Chief Executive Officer of InMed Pharmaceuticals
--->. "There are very few individuals world-wide who have Dr. Mohammed's level of expertise and direct experience in canna
--->binoid drug development.  We are very fortunate to have been able to attract such a qualified executive to the InMed t
--->eam."
Dr. Sazzad Hossain, Chief Scientific Officer, added, "Dr. Mohammed's expertise in regulatory affairs, clinical develop
--->ment and marketing in the cannabinoid based therapies is expected to add immediate value to InMed as we seek to succes
--->sfully advance our cannabinoid based therapies along the clinical and regulatory pathway."
Dr. Mohammed commented, "Joining InMed at this transformative stage, as the company prepares for clinical development 
--->of its lead programs, is the opportunity I'd been seeking to continue my passion for bringing cannabinoid therapies to
---> the market.  I look forward to leveraging my expertise in support of InMed's exciting drug candidates."
Prior to joining InMed Pharmaceuticals, Dr. Mohammed served as Associate Medical Director at GW Pharmaceuticals; a UK-
--->based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role
--->, and others at GW Pharmaceuticals, Dr. Mohammed was involved in the advanced delivery of core clinical research and w
--->as involved in key decision-making regarding R&D and product commercialization. He played a leading role in GW Pharmac
--->euticals' pharmacovigilance team where his responsibilities included handling of the company's drug safety data from b
--->oth clinical trials and post-marketing sources, and general management of safety signals including investigations, rev
--->iews and reporting. He is also a consultant to the Nigerian regulatory authority (NAFDAC) in the areas of pharmacovigi
--->lance, post-marketing surveillance and clinical trials.

Prior to joining GW Pharmaceuticals Dr. Mohammed was with PPD, a leading global contract research organization providi
--->ng drug discovery, development, lifecycle management and laboratory services. Dr. Mohammed also served as Chief Medica
--->l Officer/Clinical Director in various public healthcare establishments in Africa from 1996 to November 2010.

Dr. Mohammed's received his MD at Ahmadu Bello University, Zaria Nigeria followed by an MSc in Orthopaedics at Univers
--->ity College London. Dr. Mohammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff. H
--->e is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of P
--->harmaceutical Physicians and the International Society for Pharmacovigilance.

About InMed 
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the researc
--->h and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed
--->'s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value dri
--->vers of the company.
For more information, visit www.inmedpharma.com

ON BEHALF OF THE BOARD

"Craig Schneider"
President and CEO

Contact:

InMed Pharmaceuticals Inc.
Craig Schneider     
President and Chief Executive Officer    
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com
212-375-2664

Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750

Forward Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-look
--->ing information") within the meaning of applicable securities laws.  Forward-looking information is based on managemen
--->t's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual res
--->ults to differ materially from those described in the forward-looking statements.  Forward-looking information in this
---> news release includes statements about Dr. Mohammed joining InMed's executive management team; Dr. Mohammed's involve
--->ment in developing a clinical trial strategy and product development strategy; the expected value to InMed of Dr. Moha
--->mmed's expertise; and the expected fundamental value drivers of the company. In connection with the forward-looking in
--->formation contained in this news release, InMed has made numerous assumptions, regarding, among other things: Dr. Moha
--->mmed's continued willingness and availability to serve on the management team; the need for and efficacy of Dr. Mohamm
--->ed's role in strategy development; and the continued value of InMed's proprietary platform technology, product pipelin
--->e and accelerated development pathway. Although management considers these assumptions to be reasonable, there can be 
--->no assurance that such assumptions will prove to be correct.  Such statements involve known and unknown risks, uncerta
--->inties and other factors that may cause actual results, performance or achievements to be materially different from th
--->ose implied by such statements. Known risk factors include, among others: Dr. Mohammed may no longer be willing or abl
--->e to serve on the management team; Dr. Mohammed's expertise may not prove to be valuable for strategy development, or 
--->he may serve a different role altogether; and InMed's proprietary platform technology, product pipeline and accelerate
--->d development pathway may not return their expected level of value. 

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's continuous disclosure f
--->ilings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qua
--->lified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such f
--->orward-looking information or to publicly announce the result of any revisions to any of the forward-looking informati
--->on contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY 
--->FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.